APGE

Apogee Therapeutics (APGE)

Apogee Therapeutics Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:APGE

1 2 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/31	09 : 07	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:APGE	Apogee Therapeutics Inc
2024/05/31	09 : 05	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:APGE	Apogee Therapeutics Inc
2024/05/28	20 : 36	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:APGE	Apogee Therapeutics Inc
2024/05/28	20 : 35	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:APGE	Apogee Therapeutics Inc
2024/05/28	20 : 30	GlobeNewswire Inc.	Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD	NASDAQ:APGE	Apogee Therapeutics Inc
2024/05/23	20 : 30	GlobeNewswire Inc.	Apogee Therapeutics to Participate in Upcoming June Investor Conferences	NASDAQ:APGE	Apogee Therapeutics Inc
2024/05/16	05 : 01	GlobeNewswire Inc.	Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases	NASDAQ:APGE	Apogee Therapeutics Inc
2024/05/13	20 : 26	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:APGE	Apogee Therapeutics Inc
2024/05/13	20 : 10	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:APGE	Apogee Therapeutics Inc
2024/05/13	20 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:APGE	Apogee Therapeutics Inc
2024/05/13	20 : 00	GlobeNewswire Inc.	Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results	NASDAQ:APGE	Apogee Therapeutics Inc
2024/05/06	21 : 00	GlobeNewswire Inc.	Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference	NASDAQ:APGE	Apogee Therapeutics Inc
2024/03/25	20 : 00	GlobeNewswire Inc.	Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases	NASDAQ:APGE	Apogee Therapeutics Inc
2024/03/13	05 : 01	GlobeNewswire Inc.	Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $483 Million	NASDAQ:APGE	Apogee Therapeutics Inc
2024/03/11	19 : 01	Edgar (US Regulatory)	Form 424B4 - Prospectus [Rule 424(b)(4)]	NASDAQ:APGE	Apogee Therapeutics Inc
2024/03/08	14 : 15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:APGE	Apogee Therapeutics Inc
2024/03/08	08 : 49	GlobeNewswire Inc.	Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering	NASDAQ:APGE	Apogee Therapeutics Inc
2024/03/08	08 : 27	Edgar (US Regulatory)	Form S-1MEF - Registration adding securities to prior Form S-1 registration [Rule 462(b)]	NASDAQ:APGE	Apogee Therapeutics Inc
2024/03/06	06 : 23	GlobeNewswire Inc.	Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering	NASDAQ:APGE	Apogee Therapeutics Inc
2024/03/06	06 : 05	Edgar (US Regulatory)	Form S-1 - General form for registration of securities under the Securities Act of 1933	NASDAQ:APGE	Apogee Therapeutics Inc
2024/03/05	22 : 15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:APGE	Apogee Therapeutics Inc
2024/03/05	20 : 15	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:APGE	Apogee Therapeutics Inc
2024/03/05	20 : 11	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:APGE	Apogee Therapeutics Inc
2024/03/05	20 : 10	GlobeNewswire Inc.	Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results	NASDAQ:APGE	Apogee Therapeutics Inc
2024/03/05	20 : 00	GlobeNewswire Inc.	Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of Sch	NASDAQ:APGE	Apogee Therapeutics Inc
2024/03/05	06 : 01	GlobeNewswire Inc.	Apogee to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases on March 5, 2024	NASDAQ:APGE	Apogee Therapeutics Inc
2024/01/02	21 : 30	GlobeNewswire Inc.	Apogee Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference	NASDAQ:APGE	Apogee Therapeutics Inc
2023/12/21	10 : 01	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:APGE	Apogee Therapeutics Inc
2023/11/13	21 : 45	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:APGE	Apogee Therapeutics Inc
2023/11/13	21 : 41	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:APGE	Apogee Therapeutics Inc